Stockreport

Evommune, Inc. GAAP EPS of -$8.07, revenue of $10M [Seeking Alpha]

Evommune, Inc.  (EVMN) 
PDF As of September 30, 2025, the Company had cash, cash equivalents and investments of $76.0 million, compared to $72.0 million as of December 31, 2024. More on Evommune [Read more]